Research of Intensive Metabolic Intervention Before Pregnancy in PCOS

NCT03383068 on ClinicalTrials.gov · last registry update 2017-12-26

An unusually large phase 4: 160 participants, more than double the 75 typical for the stage. Its estimated completion date, 31 December 2018, has passed with no update to the record. Primary outcome, as filed: Improvement of pregnant rate after intensive metabolic intervention. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. exenatide is approved in the US, but not for pcos and prediabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: UNKNOWN
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: RenJi Hospital
Sponsor type: Other
Enrollment: 160
Started: 2018-01-01
Primary completion: 2018-12-31 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Improvement of pregnant rate after intensive metabolic intervention

Conditions studied

PCOS · Impaired Glucose Tolerance

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.